login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
CYTOMX THERAPEUTICS INC (CTMX) Stock News
USA
- NASDAQ:CTMX -
US23284F1057
-
Common Stock
3.37
USD
+0.04 (+1.2%)
Last: 10/8/2025, 8:00:01 PM
3.36
USD
-0.01 (-0.3%)
After Hours:
10/8/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CTMX Latest News, Press Relases and Analysis
All
Press Releases
13 days ago - By: Chartmill
- Mentions:
LPTH
SOS
IPDN
CNXC
...
What's going on in today's after hours session
13 days ago - By: The Motley Fool
Why CytomX Therapeutics Stock Was Skyrocketing This Week
13 days ago - By: Benzinga
- Mentions:
XRTX
DRIO
MTNB
ORGO
...
12 Health Care Stocks Moving In Thursday's After-Market Session
a month ago - By: Benzinga
- Mentions:
INHD
SER
CAPS
NXTT
...
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
2 months ago - By: The Motley Fool
CytomX (CTMX) Q2 Revenue Drops 26%
2 months ago - By: Zacks Investment Research
- Mentions:
OCS
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2
2 months ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
2 months ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
4 months ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
5 months ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
5 months ago - By: Stocktwits
CytomX Stock Hits 2-Month High After Upbeat Q1 Earnings, Promising Early Data For Cancer Drug
5 months ago - By: Zacks Investment Research
- Mentions:
SEER
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates
5 months ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
5 months ago - By: CytomX Therapeutics Inc.
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)
5 months ago - By: CytomX Therapeutics Inc.
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
5 months ago - By: Zacks Investment Research
- Mentions:
SWTX
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates
Please enable JavaScript to continue using this application.